Medical tech firm LivaNova beats Q3 revenue expectations, raises 2025 guidance

Livanova

05/11/2025 11:15

Overview

LivaNova Q3 revenue grows 12.5%, beating analyst expectations

Adjusted EPS for Q3 beats consensus, reflecting strong operational performance

Company raises 2025 revenue and EPS guidance, reflecting confidence in growth

Outlook

LivaNova raises full-year 2025 revenue growth guidance to 8.5%-9.5% constant-currency

Company expects 2025 adjusted EPS to be $3.80-$3.90

LivaNova estimates 2025 adjusted free cash flow at $160 mln-$180 mln

Result Drivers

CARDIOPULMONARY GROWTH - Revenue increased 18% driven by Essenz Perfusion System sales and strong consumables demand

NEUROMODULATION GROWTH - Revenue rose 6.9% with growth across all regions

OPERATING MARGIN EXPANSION - Driven by disciplined execution and enhanced productivity

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Revenue
Beat
$357.80 mln
$343.50 mln (7 Analysts)
Q3 Adjusted EPS
Beat
$1.11
$0.91 (9 Analysts)
Q3 EPS
$0.49


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy", 3 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

Wall Street's median 12-month price target for LivaNova PLC is $60.50, about 10.8% above its November 4 closing price of $53.94

The stock recently traded at 13 times the next 12-month earnings vs. a P/E of 11 three months ago

Press Release: ID:nBw8Z7fh2a

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)